Qiagen N.V. (NYSE:QGEN) Given Consensus Rating of “Hold” by Brokerages

Shares of Qiagen N.V. (NYSE:QGEN) have received a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $43.9250.

Several equities research analysts recently issued reports on QGEN shares. TD Cowen reiterated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Stifel Nicolaus set a $40.00 target price on Qiagen in a report on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Robert W. Baird set a $43.00 price target on shares of Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $43.00 price target on shares of Qiagen in a research report on Thursday, April 30th.

Qiagen Stock Up 0.6%

Qiagen stock opened at $43.25 on Friday. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The firm has a 50 day moving average price of $39.97 and a 200 day moving average price of $41.31. The company has a market capitalization of $8.91 billion, a PE ratio of 22.16, a price-to-earnings-growth ratio of 4.28 and a beta of 0.63.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The company had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the prior year, the firm earned $0.60 earnings per share. The firm’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts expect that Qiagen will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

A number of hedge funds have recently added to or reduced their stakes in the business. Canvas Wealth Advisors LLC boosted its position in Qiagen by 90.2% in the 2nd quarter. Canvas Wealth Advisors LLC now owns 30,119 shares of the company’s stock valued at $1,178,000 after buying an additional 14,281 shares during the period. Handelsbanken Fonder AB purchased a new stake in shares of Qiagen during the second quarter worth $2,909,000. GAMMA Investing LLC increased its position in shares of Qiagen by 70.4% during the second quarter. GAMMA Investing LLC now owns 3,521 shares of the company’s stock worth $138,000 after acquiring an additional 1,455 shares during the period. Hilltop National Bank purchased a new stake in shares of Qiagen during the second quarter worth $50,000. Finally, Groupama Asset Managment acquired a new stake in shares of Qiagen in the first quarter valued at $500,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.